ReShape Lifesciences Operating Income 2015-2024 | RSLS

ReShape Lifesciences operating income from 2015 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.

ReShape Lifesciences Operating Income 2015-2024 | RSLS

ReShape Lifesciences operating income from 2015 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Related Stocks
Company NameMarket
Cap
Thermo Fisher Scientific (TMO)$233.1B
Intuitive Surgical (ISRG)$171.3B
Alcon (ALC)$47.7B
IQVIA Holdings (IQV)$44.2B
IDEXX Laboratories (IDXX)$42.1B
Edwards Lifesciences (EW)$40.7B
DexCom (DXCM)$27.8B
STERIS (STE)$23.5B
SONOVA HOLDING (SONVY)$20.8B
Waters (WAT)$19.8B
Hologic (HOLX)$19B
Sysmex ADR (SSMXY)$12.3B
Fresenius Medical Care AG KGaA (FMS)$12.2B
Teleflex (TFX)$11.4B
Globus Medical (GMED)$9.4B
Penumbra (PEN)$7.6B
Glaukos (GKOS)$6.7B
Masimo (MASI)$6.1B
TransMedics (TMDX)$5.2B
PROCEPT BioRobotics (PRCT)$4.3B
Integer Holdings (ITGR)$4.3B
Tandem Diabetes Care (TNDM)$2.8B
LivaNova (LIVN)$2.8B
Veracyte (VCYT)$2.6B
Inari Medical (NARI)$2.6B
Elekta AB (EKTAY)$2.6B
Nihon Kohden (NHNKY)$2.5B
RxSight (RXST)$2B
Integra LifeSciences Holdings (IART)$1.4B
Pulse Biosciences (PLSE)$1.2B